Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pamplona
Clinical trial register · Spain

Clinical Trials in Pamplona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC44 AstraZeneca41 Novartis Pharmaceuticals22 AbbVie20 Fundacion Miguel Servet18
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Pamplona

612 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Active, closed
AstraZeneca
Phase 3
185
Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Granada, Madrid, Pamplona, Valencia
2020-08-04
Active, closed
Boehringer Ingelheim
Phase 1
306
Barcelona, Pamplona, Valencia
2020-07-29
Recruiting
BioInvent International AB
Phase 1/2
197
Barcelona, Majadahonda, Málaga, Pamplona, Seville
2020-06-29
Active, closed
Sanofi
Phase 3
337
Barcelona, Pamplona, Valencia, Madrid, Salamanca, Zaragoza
2020-06-16
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville
2020-06-12
Active, closed
Epizyme, Inc.
Phase 3
599
Barcelona, Marbella, El Palmar, Madrid, Pamplona, Salamanca, Seville
2020-06-11
Active, closed
Lifestyles and Breast Cancer
NCT04174391Malignant Tumor of Breast
University of Navarra
Not applicable
766
Santander, Granada, Jaén, Pamplona
2020-05-29
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
Badalona, L'Hospitalet de Llobregat, Pamplona, Oviedo, Barcelona, Cáceres, Girona, Granada
2020-05-21
Recruiting
High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
NCT06982469Prostate Cancer, Prostatectomy, Local Recurrence of Malignant Tumor of Prostate, Radiotherapy; Complications
Clinica Universidad de Navarra, Universidad de Navarra
Observational
20
Pamplona
2020-05-05
Recruiting
EORTC Metastatic Breast Cancer Module Development
NCT07806266Metastatic Beast Cancer
University of Leeds
Observational
568
Pamplona
2020-05-01
Recruiting
Proton Therapy Medical Registry
NCT05151952Cancer, Therapy-Related
Clinica Universidad de Navarra, Universidad de Navarra
Observational
6,000
Pamplona, Madrid
2020-04-01
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Barcelona, Córdoba, Lugo, Madrid, Manresa, Pamplona, Sabadell, Santander
2020-03-30
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
75
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Seville, Valencia
2020-03-12
Recruiting
InnoUp Farma S.L.
Phase 1/2
50
Pamplona
2020-03-11
Recruiting
University of Leicester
Not applicable
2,104
Barcelona, Pamplona
2020-03-10
Recruiting
Amgen
Phase 1
479
Barcelona, Pamplona, Madrid
2020-03-04
Active, closed
Immunocore Ltd
Phase 1/2
410
Pamplona, Barcelona, Madrid
2020-02-25
Active, closed
Janssen Research & Development, LLC
Phase 1
290
Barcelona, Madrid, Pamplona, Salamanca
2020-02-21
Active, closed
Eli Lilly and Company
Phase 3
261
Palma de Mallorca, Badalona, Santiago de Compostela, Las Palmas de Gran Canaria, Majadahonda, Pamplona, Alicante, Barcelona
2020-02-17
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Barcelona, L'Hospitalet de Llobregat, Girona, Madrid, Málaga, Pamplona, Zaragoza
2020-02-11
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Badalona, Pamplona, San Cristóbal de La Laguna, Barcelona, Jaén, Madrid, Seville, Valencia
2020-01-29
Active, closed
Pfizer
Phase 3
1,068
Badalona, Granollers, L'Hospitalet de Llobregat, Majadahonda, Pamplona, Reus, A Coruña, Barcelona
2019-12-30
Active, closed
Galderma R&D
Phase 3
1,700
Alicante, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona
2019-12-30
Active, closed
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
DrugTobemstomig
Hoffmann-La Roche
Phase 1/2
170
Pamplona, Barcelona, Madrid
2019-11-11
Active, closed
AbbVie
Phase 1
85
L'Hospitalet de Llobregat, Pamplona, Madrid
2019-11-08
Active, closed
Janssen Research & Development, LLC
Phase 2
208
Pamplona, Salamanca
2019-11-07
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
A Coruña, Barcelona, Las Palmas, Madrid, Málaga, Pamplona, Valencia
2019-10-31
Active, closed
Nouscom SRL
Phase 1/2
115
A Coruña, Barcelona, Córdoba, Granada, Madrid, Pamplona, Salamanca, Santander
2019-10-21
Active, closed
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
DrugsVusolimogene Oderparepvec·Cemiplimab
Replimune, Inc.
Phase 2
231
Barcelona, Madrid, Murcia, Pamplona, Valencia
2019-10-08
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Pamplona, Barcelona, Madrid, Seville
2019-10-03
Active, closed
Celgene
Phase 1/2
424
Badalona, Madrid, Málaga, Pamplona, Salamanca, Santander, Valencia
2019-09-30
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Palma, Pamplona, Sabadell
2019-09-18
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona, Santiago de Compostela
2019-09-17
Active, closed
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
NCT03993873Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Turning Point Therapeutics, Inc.
Phase 1
95
Madrid, Pamplona
2019-09-05
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Donostia / San Sebastian, Majadahonda, Pamplona, A Coruña, Alicante, Badalona, Barcelona, Burgos
2019-08-09
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Badalona, Barcelona, Madrid, Pamplona, Valencia
2019-08-09
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
150
L'Hospitalet de Llobregat, Pamplona
2019-08-01
Active, closed
Amgen
Phase 3
457
Seville, Barcelona, Pamplona, Valencia
2019-07-19
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
197
Badalona, Madrid, Pamplona, Valencia
2019-07-17
Active, closed
Exelixis
Phase 3
855
Santiago de Compostela, Pamplona, Barcelona, Córdoba, Madrid, Oviedo, Valencia
2019-06-25
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Observational
2,000
Badalona, Barcelona, Cartagena, Córdoba, Madrid, Pamplona, Salamanca, Terrassa
2019-06-24
Active, closed
Bristol-Myers Squibb
Phase 3
437
Barcelona, Córdoba, Madrid, Pamplona, Sabadell, Santander, Santiago Compostela, Seville
2019-06-21
Recruiting
Population Health Research Institute
Phase 4
2,270
Barcelona, Madrid, Pamplona
2019-06-14
Active, closed
Eisai Inc.
Phase 2
100
Madrid, Pamplona, Santiago de Compostela, Seville
2019-05-31
Active, closed
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Observational
1,508
Santiago de Compostela, Pamplona, Barcelona, Córdoba, Granada, Tarragona, Valencia, Zaragoza
2019-05-27
Active, closed
Novo Nordisk A/S
Phase 3
1,500
A Coruña, Barcelona, L'Hospitalet de Llobregat, Pamplona, Seville, Valencia
2019-05-08
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Llobregat, Pamplona, Barcelona, Cáceres, Córdoba, Lleida, Madrid, Málaga
2019-03-15
Active, closed
Follow-up in Gynecological Cancer Survivors
NCT03515993Gynecologic Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,100
Madrid, Pamplona, Salamanca
2019-02-21
Active, closed
AbbVie
Phase 1
364
Pamplona, Barcelona, Madrid, Valencia
2019-02-21
Active, closed
University Hospital, Montpellier
Phase 2/3
113
Barcelona, Pamplona, Valladolid
2019-02-18
Active, closed
Xenon Pharmaceuticals Inc.
Phase 2
325
Seville, Badalona, Pamplona, Barcelona, Granada, Madrid, Málaga, Valencia
2019-01-30
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
387
Barcelona, Pamplona, Madrid, Salamanca
2019-01-23
Recruiting
Results of Surgical Treatment of the Hepatobiliopancreatic Surgical Unit
NCT04556019Pancreas Disease, Liver Diseases, Surgical Procedure, Unspecified, Bile Duct Diseases
Fundacion Miguel Servet
Observational
1,000
Pamplona
2019-01-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Lugo, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Valencia
2018-12-24
Active, closed
AstraZeneca
Phase 3
825
Alicante, Barcelona, Donostia / San Sebastian, Madrid, Málaga, Oviedo, Pamplona, Santiago de Compostela (A Coruña)
2018-12-06
Active, closed
AstraZeneca
Phase 3
724
Córdoba, Madrid, Pamplona, San Sebastián(Guipuzcoa)
2018-11-30
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
A Coruña, Barcelona, Elche, Madrid, Málaga, Pamplona, Valencia
2018-11-28
Recruiting
Hoffmann-La Roche
Phase 3
1,000
L'Hospitalet de Llobregat, San Cugat Del Valles, Majadahonda, Pamplona, Oviedo, Burjassot, Barcelona, Córdoba
2018-09-20
Recruiting
Celgene
Phase 2/3
1,541
Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Málaga, Pamplona, Salamanca, Santander
2018-07-19
Active, closed
PETHEMA Foundation
Phase 2
62
Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Murcia, Oviedo, Pamplona
2018-07-15
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
DrugEpcoritamab
Genmab
Phase 1/2
666
Pamplona, Badalona, Barcelona, Madrid
2018-06-26
Active, closed
Exelixis
Phase 3
837
Santander, Majadahonda, Pamplona, Barcelona, Madrid, Valencia, Zaragoza
2018-06-10
Active, closed
Canadian Cancer Trials Group
Phase 2
129
Pamplona, Barcelona, Madrid, Valencia
2018-05-28
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
890
Pamplona, Badalona, Barcelona, Madrid, Santiago de Compostela
2018-05-21
Active, closed
AstraZeneca
Phase 3
1,018
Badajoz, Barcelona, Elche(Alicante), Madrid, Málaga, Oviedo, Pamplona, Pozuelo de Alarcón
2018-05-14
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Barcelona, Madrid, Pamplona, Zaragoza
2018-05-03
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
DrugPetosemtamab
Merus B.V.
Phase 1/2
560
Barcelona, Madrid, Pamplona, Valencia
2018-05-02
Active, closed
MedImmune LLC
Phase 1
400
A Coruña, Barcelona, Majadahonda, Málaga, Pamplona, Valencia
2018-04-24
Active, closed
Bristol-Myers Squibb
Phase 3
545
Barcelona, Córdoba, Donostia / San Sebastian, Madrid, Pamplona, Sabadell (Barcelona), Seville, Valencia
2018-04-18
Active, closed
Janssen Research & Development, LLC
Phase 3
211
Barcelona, Madrid, Pamplona, Salamanca, Seville
2018-04-17
Active, closed
AbbVie
Phase 3
747
Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, A Coruña, Barcelona, Girona, Huelva
2018-03-21
Active, closed
InSightec
Not applicable
92
Móstoles, Pamplona
2018-02-09
Recruiting
Spanish Breast Cancer Research Group
Observational
8,000
Pamplona, Avilés, San Cristóbal de La Laguna, A Coruña, Albacete, Alicante, Badajoz, Badalona
2018-01-18
Active, closed
Janssen Research & Development, LLC
Phase 1
279
Badalona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca
2017-12-16
Active, closed
BeiGene
Phase 3
590
Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Valencia, Zaragoza
2017-10-31
Active, closed
Daiichi Sankyo
Phase 1
312
Barcelona, Madrid, Pamplona
2017-10-30
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
885
Alcorcón, Barcelona, Bilbao, Cartagena, Córdoba, Las Palmas de Gran Canaria, Pamplona, Sabadell
2017-09-25
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
L'Hospitalet de Llobregat, Santiago de Compostela, Pamplona, Alicante, Barcelona, Madrid, Málaga, Seville
2017-09-22
Active, closed
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
NCT03212404Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
Checkpoint Therapeutics, Inc.
Phase 1
272
Barcelona, Madrid, Málaga, Pamplona, San Cristóbal de La Laguna, Seville, Valencia
2017-09-20
Active, closed
Hoffmann-La Roche
Phase 3
382
Palma de Mallorca, Córdoba, A Coruña, Las Palmas de Gran Canaria, Pamplona, Barcelona, Cáceres, Jaén
2017-09-20
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab
Replimune, Inc.
Phase 2
340
Barcelona, Madrid, Murcia, Pamplona, Seville, Valencia
2017-09-20
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
DrugsCabozantinib·Tecentriq·Atezolizumab
Exelixis
Phase 1
914
Santiago de Compostela, Elche, Palma de Mallorca, Badalona, Sabadell, Jeréz de La Frontera, Pamplona, Oviedo
2017-09-05
Active, closed
Janssen Research & Development, LLC
Phase 1
302
Badalona, Barcelona, Pamplona, Salamanca
2017-05-16
Active, closed
Pfizer
Phase 3
296
L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Majadahonda, Pamplona, A Coruña, Barcelona, Girona, Madrid
2017-04-27
Active, closed
Acerta Pharma BV
Phase 3
635
Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Seville, Valencia
2017-04-05
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Barcelona, Madrid, Pamplona, Valencia
2017-03-07
Active, closed
AbbVie
Phase 3
443
Pamplona, Barcelona, Madrid, Málaga, Valencia
2017-02-02
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Barcelona, Girona, Madrid, Pamplona, Salamanca, Santiago de Compostela
2016-12-22
Active, closed
Target PharmaSolutions, Inc.
Observational
10,000
Madrid, Pamplona, Santander, Seville, Valencia
2016-12
Active, closed
Janssen Research & Development, LLC
Phase 1/2
234
Badalona, Barcelona, Madrid, Málaga, Pamplona, Seville, Valencia
2016-11-21
Active, closed
Celgene
Phase 1/2
466
Badalona (Barcelona), Barcelona, Madrid, Pamplona, Valencia
2016-10-14
Active, closed
Tesaro, Inc.
Phase 1
729
Santiago de Compostela, Barcelona, Girona, Madrid, Málaga, Murcia, Pamplona, Santander
2016-03-07
Active, closed
MedImmune LLC
Phase 1/2
383
Barcelona, Madrid, Málaga, Pamplona, Seville
2016-02-22
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Barcelona, Córdoba, Jerez de la Frontera, Madrid, Pamplona
2015-11-27
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Esplugues, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2015-11-02
Active, closed
MedImmune LLC
Phase 2
433
Barcelona, Córdoba, Pamplona
2015-10-19
Active, closed
Phase III Radium 223 mCRPC-PEACE III
NCT02194842Prostate Cancer
DrugsRa223·Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
446
Barcelona, Madrid, Pamplona, Sabadell, Salamanca
2015-10
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Girona, Pamplona, Madrid
2015-07-14
Active, closed
Eli Lilly and Company
Phase 3
545
Barcelona, Hospitalet, Palma, Pozuelo de Alarcón, Madrid, Pamplona, Seville, Valencia
2015-05-06
Active, closed
PETHEMA Foundation
Phase 2
90
Barcelona, Madrid, Murcia, Oviedo, Pamplona, Plama de Mallorca, Salamanca, Santa Cruz de Tenerife
2015-05
Active, closed
Janssen Research & Development, LLC
Phase 2
239
Badalona, Barcelona, Madrid, Málaga, Pamplona, Sabadell, Santander, Santiago de Compostela
2015-04-22
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Barcelona, Pamplona, Salamanca
2015-03-05
Active, closed
Acerta Pharma BV
Phase 2
124
Badalona, Pamplona
2015-03-02
Active, closed
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
DrugBispecific
Partner Therapeutics, Inc.
Phase 2
250
Barcelona, Madrid, Pamplona, Valencia
2015-01
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Badalona, Barcelona, Madrid, Palma de Mallorca, Pamplona, Salamanca, Seville
2014-11
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca
2013-09-09
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Barcelona, Córdoba, Girona, Madrid, Pamplona, Valencia
2013-09-03
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Barcelona, Pamplona, Seville
2013-03-18
Recruiting
Boston Scientific Corporation
Observational
4,800
Ciudad Real, Madrid, Pamplona, San Sebastián, Santander, Toledo, Valencia
2012-11-19
Recruiting
CHDI Foundation, Inc.
Observational
35,000
Badajoz, Barakaldo, Barcelona, Burgos, Madrid, Palma de Mallorca, Pamplona, Valencia
2012-07
Active, closed
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
NCT01385176Heart Failure, Congestive Heart Failure
Boston Scientific Corporation
Not applicable
118
Pamplona, Barcelona, Madrid
2011-09-21
By invitation
Dynamic Mediterranean Prospective Cohort: the SUN Project
NCT02669602Lifestyle, Chronic Disease, Dietary Habits
Clinica Universidad de Navarra, Universidad de Navarra
Observational
22,500
Pamplona
1999-12
Rows per page Showing 501–612 of 612
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/pamplona?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 612 of those studies with a site in Pamplona.

How many clinical trials are recruiting in Pamplona?

294 of the 612 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 21 have not yet opened recruitment, 281 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.